Rashid Sk Mamun Ur, Sumaria Sheetal, Koohi Nehzat, Arshad Qadeer, Kaski Diego
Department of Neuro-Otology, Royal National Ear Nose and Throat Hospital, University College London Hospitals, London WC1E 6DG, UK.
Department of Pharmacy, National Hospital for Neurology and Neurosurgery, London WC1N 3BG, UK.
Brain Sci. 2022 Mar 22;12(4):415. doi: 10.3390/brainsci12040415.
Vestibular migraine (VM) is a leading cause of episodic vertigo, affecting up to 1% of the general population. Despite established diagnostic criteria, there is currently no evidence-based approach for acute treatment of VM, with treatment recommendations generally extrapolated from studies on classical migraine headache. Several small-scale studies have identified flunarizine as a potentially effective prophylactic medication in VM. We conducted a single-centre observational service evaluation study exploring patient experiences of preventative medications over a 28-month period, including flunarizine, for control of VM symptoms. To compare patient experience of flunarizine with other medications, data from patients taking flunarizine were separately analysed. A total of 90% of VM patients taking flunarizine reported symptomatic improvement, compared to only 32% of patients on other medications. Whilst 50% of patients on flunarizine reported side effects. these were not deemed to outweigh the clinical benefits, with most patients deciding to continue treatment. Our data supports the use of flunarizine in VM.
前庭性偏头痛（VM）是发作性眩晕的主要原因，影响着高达1%的普通人群。尽管有既定的诊断标准，但目前尚无基于证据的VM急性治疗方法，治疗建议通常是从经典偏头痛性头痛的研究中推断出来的。几项小规模研究已确定氟桂利嗪是VM中一种潜在有效的预防性药物。我们进行了一项单中心观察性服务评估研究，探讨了在28个月期间包括氟桂利嗪在内的预防性药物对控制VM症状的患者体验。为了比较氟桂利嗪与其他药物的患者体验，对服用氟桂利嗪患者的数据进行了单独分析。服用氟桂利嗪的VM患者中有90%报告症状有所改善，而服用其他药物的患者中只有32%有此情况。虽然服用氟桂利嗪的患者中有50%报告有副作用，但这些副作用被认为并未超过临床益处，大多数患者决定继续治疗。我们的数据支持在VM中使用氟桂利嗪。
